Health score, competitive moat, risk signals, and key metrics at a glance.
OSI Systems, Inc. designs and manufactures electronic systems and components in the United States and internationally. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The company offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems, and radio frequency (RF) equipment under the Rapiscan name. It also provides site design, installation, training, and technical support services; and turnkey security screening solutions under the S2 name. In addition, the company offers patient monitoring, cardiology and remote monitoring, and connected care systems and accessories under the Spacelabs name for use in critical care, emergency, and perioperative areas within hospitals, physicians' offices, medical clinics, and ambulatory surgery centers. Further, it provides optoelectronic devices and flex circuits under the OSI Optoelectronics, OSI LaserDiode, and Advanced Photonix names for the aerospace and defense, avionics, medical imaging and diagnostics, biochemistry analysis, pharmaceutical, nanotechnology, telecommunications, construction, and homeland security markets. Additionally, the company offers electronics manufacturing services to original equipment manufacturers and end users for medical, automotive, defense, aerospace, industrial, and consumer applications under the OSI Electronics, APlus Products, Altaflex, and PFC Flexible Circuits names; and LCD displays for medical, industrial, and consumer electronics applications. The company was incorporated in 1987 and is headquartered in Hawthorne, California.
Competitive analysis based on 56 quarters of fundamental data
Operating margins are expanding at ~11.7%, suggesting durable pricing power and cost discipline.
Consistently high ROE averaging 19.7% suggests a durable competitive advantage and efficient capital allocation.
Data-driven red flags and warnings across 56 quarters
Margins are stable or improving at ~11.9% — no sign of cost or pricing stress.
FCF consistently trails net income (avg -0.1x) — earnings may be inflated by non-cash items or aggressive accounting.
Debt-to-equity has risen 111.2% recently — increasing financial risk even if the current ratio is manageable.
Revenue is stable or growing over recent quarters — demand appears durable.
FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.
Shares decreased 3.0% — net buybacks are reducing shares outstanding and boosting per-share value.
as of March 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
5 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
